Evidence map›Paper›PMID 30348728›Full record

ArticleIn vivo (Athens, Greece)

Safety and Efficacy of Trifluridine-Tipiracil Hydrochloride Oral Combination (TAS-102) in Patients with Unresectable Colorectal Cancer.

Satoshi Narihiro, Katsuhito Suwa, Takuro Ushigome, Masamichi Ohtsu, Syunjin Ryu, Yuya Shimoyama, Tomoyoshi Okamoto, Katsuhiko Yanaga

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Satoshi NarihiroDepartment of Surgery, The Jikei University Daisan Hospital, Tokyo, Japan nasa1355@yahoo.co.jp.
Katsuhito SuwaDepartment of Surgery, The Jikei University Daisan Hospital, Tokyo, Japan.
Takuro UshigomeDepartment of Surgery, The Jikei University Daisan Hospital, Tokyo, Japan.
Masamichi OhtsuDepartment of Surgery, The Jikei University Daisan Hospital, Tokyo, Japan.
Syunjin RyuDepartment of Surgery, The Jikei University Daisan Hospital, Tokyo, Japan.
Yuya ShimoyamaDepartment of Surgery, The Jikei University Daisan Hospital, Tokyo, Japan.
Tomoyoshi OkamotoDepartment of Surgery, The Jikei University Daisan Hospital, Tokyo, Japan.
Katsuhiko YanagaDepartment of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
The Jikei University Hospital · JPJikei University School of Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo retrospectively examine efficacy and safety of oral combination of trifluridine and tipiracil hydrochloride (TAS-102) as the second-line therapeutic agent for unresectable colorectal cancer. PATIENT AND

methodsTreatment outcomes of 17 patients who had received TAS-102 at our Institution from January 2015 to January 2017 were analyzed. The indications for second-line TAS-102 treatment were intolerance to other multi-drug combination (four patients) or patient refusal of the standard second-line therapy (13 patients).

resultsAmong 17 patients who received TAS-102 as second-line therapy, partial response was observed in two (12%) and stable disease in two (12%). Outcomes of TAS-102 given as second-line therapy were: median overall survival of 5 months, response rate of 12% and disease control of 24%. Overall, no adverse events other than neutropenia were noted.

conclusionOur findings suggest a beneficial role of TAS-102 in second-line therapy for unresectable colorectal carcinoma.

Indexed as

Administration, OralAdultAgedAntineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsDisease-Free SurvivalDrug CombinationsFemaleHumansMaleMiddle AgedPyrrolidinesThymineTreatment OutcomeTrifluridineUracilDrug CombinationsPyrrolidinesThymineTrifluridinetrifluridine tipiracil drug combinationUracilchemotherapyTAS-102unresectable colorectal carcinoma

Identifiers

PMID30348728
PMCPMC6365739
OpenAlexW2897057835

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.